Cell Therapy Archives | Page 18 of 60

Altaris Launches Minaris Advanced Therapies, Merging the CDMOs Minaris Regenerative Medicine and WuXi Advanced Therapies

May 6, 2025 By Cade Hildreth, Founder & President Leave a Comment

Combined Entity will be a Global CDMO Powerhouse in Cell and Gene Therapy

In a bold move that has consolidated the landscape of advanced therapy manufacturing, Altaris LLC announced the successful acquisition of two key cell and gene therapy operations—Advanced Therapies U.S. and OXGENE—from WuXi AppTec. Completed on March 7, 2025, the transaction marks a strategic expansion of Altaris’ footprint in the fast-growing cell and gene therapy contract development and manufacturing organization (CDMO) space. [Read more…]

Nikon CeLL Innovation Enters into a Strategic License Agreement with RoosterBio, a US Company, to Enable GCTP/GMP Manufacturing Platform of Human Mesenchymal Stem Cells & Extracellular Vesicle in Japan

May 2, 2025 By BioInformant Team Leave a Comment

TOKYO – Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBio), a leading stem cell technology company in the US.

This agreement provides the Japanese biopharma industry with an end-to-end solution for development and manufacturing of human mesenchymal stem cells (MSC) and extracellular vesicle (EV) therapeutics. Drug developers can leverage RoosterBio’s technology platform to accelerate the development of their advanced therapies with NCLi, and then seamlessly transition to clinical manufacturing within NCLi’s GCTP*1/GMP*2 facility designed specifically for cell therapies. [Read more…]

Exploring Personal Stem Cell Banking within Regenerative Medicine: A Conversation with Kevin Ferber, COO of American Cell Technology

April 7, 2025 By BioInformant Team 1 Comment

As the world of healthcare continues to evolve, regenerative medicine is emerging as a cornerstone of personalized, proactive health. In line with the mission of the 2025 HEALinc Global Summit – which aims to restore whole-person health through cutting-edge technologies, mentorship and education – the potential of stem cell therapy is poised to redefine our approach to health, longevity and wellness. Founded in 2018 by Dr. Desirée Cox (MD, MPhil, PhD), the HEALinc Global Summit brings together leaders and innovators to explore the latest scientific breakthroughs in healthy longevity and regenerative medicine. This year’s Summit will be held at the Atlantis Resort in The Bahamas from April 27^th – 29^th, 2025. [Read more…]

RoslinCT and Ayrmid Pharma Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv)

March 20, 2025 By Cade Hildreth, Founder & President Leave a Comment

Intent that RoslinCT is to perform technology transfer and commercial manufacture of Omisirge® at RoslinCT’s cell therapy manufacturing facility in Hopkinton, MA.

Omisirge® is a commercialized mismatched unrelated cell therapy derived from the youngest donor source and banked for ease of infusion for patients with hematological malignancies.

[Read more…]

Garuda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell Therapies

March 13, 2025 By BioInformant Team Leave a Comment

New funding will accelerate Garuda’s rapid growth and fund development of off-the-shelf hematopoietic stem cell (HSC) therapies for a multitude of severe and life-threatening diseases

CAMBRIDGE, Mass., March 04, 2025 — Garuda Therapeutics (Garuda), a biotechnology company creating off-the-shelf, HSC therapies for a multitude of blood disorders, today announced the successful completion of an approximately $50 million Series A-1 funding round. Investors included OrbiMed, Northpond Ventures and Cormorant Asset Management, with new strategic investment from Kyowa Kirin Co., Ltd., a Japan-based Global Specialty Pharmaceutical Company. [Read more…]